ストックスクリーナーアプリを入手
442.05
1.13%
-5.04
Vertex Pharmaceuticals Inc (VRTX) 最新ニュース
Transcript : Vertex Pharmaceuticals Incorporated Presents at Bernstein 41st Annual Strategic Decisions Conference 2025, May-30-2025 08 - marketscreener.com
Vertex at Bernstein Conference: Strategic Growth and Innovation - Investing.com
Vertex at Bernstein Conference: Strategic Growth and Innovation By Investing.com - Investing.com UK
Vertex Pharmaceuticals (VRTX) Gets a Hold from RBC Capital - The Globe and Mail
If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today - Benzinga
Harvard Professor to Chief Medical Officer: Wave Life Sciences Taps RNA Expert Behind Breakthrough FDA Approvals - Stock Titan
Great Valley Advisor Group Inc. Raises Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow - AOL.com
Eli Lilly Commits $1B to Get Drug That Could Rival Vertex’s New Non-Opioid Pain Med - MedCity News
Lilly to buy pain drug developer SiteOne, challenging Vertex - BioPharma Dive
Lilly lands next-gen pain asset in $1B SiteOne acquisition - Fierce Biotech
Vertex Pharmaceuticals’ SWOT analysis: cystic fibrosis leader faces diversification challenges - Investing.com
Vertex Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish? - MSN
ViewPoints: Vertex’s triplet data raise bar and turn screws on CF competition - FirstWord Pharma
Vertex divulges new Nav1.8 blockers for pain - BioWorld MedTech
2 Monster Growth Stocks to Buy and Hold for 10 Years - The Motley Fool
Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline? (NASDAQ:VRTX) - Seeking Alpha
Argus Adjusts Price Target on Vertex Pharmaceuticals to $525 From $550 - marketscreener.com
Vertex Pharmaceuticals (VRTX) Downgraded Due to High Inventory L - GuruFocus
Vertex Pharmaceuticals (VRTX) Announces $4 Billion Share Buyback Program - GuruFocus
Gilead and Vertex Pharma named among biotech’s tariff safe havens - MSN
Vertex Pharma announces new share buybacks worth up to $4B - MSN
Vertex Pharmaceuticals Stock Outlook: Is Wall Street Bullish Or Bearish? - Barchart.com
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 - Yahoo Finance
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years - Benzinga
Vertex Pharma stock gains on share buybacks (VRTX:NASDAQ) - Seeking Alpha
Vertex Pharmaceuticals (VRTX) Announces New $4 Billion Stock Rep - GuruFocus
Vertex Pharmaceuticals Authorizes $4 Billion In Additional Share Repurchases - marketscreener.com
August 15th Options Now Available For Vertex Pharmaceuticals (VRTX) - Nasdaq
VRTX Q1 Earnings Call: New Product Launches and Pipeline Progress Amid Revenue Miss - Yahoo Finance
Vertex to Participate in Upcoming Investor Conferences | VRTX Stock News - GuruFocus
Vertex to Participate in Upcoming Investor Conferences - Business Wire
Narrow-Moat Vertex's Long-Term Growth Supported by Strong Cash Flows From CF Franchise - Morningstar
Vertex Pharmaceuticals Holds Annual Shareholder Meeting - TipRanks
Stifel maintains hold on Vertex stock with $494 target - Investing.com
$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today - Benzinga
Best Biotech Stocks to Buy in 2025 - MarketBeat
Fund Update: TRILLIUM ASSET MANAGEMENT, LLC added 38,854 shares of VERTEX PHARMACEUTICALS ($VRTX) to their portfolio - Nasdaq
Our future journey in cystic fibrosis - Vertex Pharmaceuticals
Vertex says late-stage studies of VX-659 triple combination therapy in CF hit main goals - FirstWord Pharma
ViewPoints: Vertex settles on a dynastic successor - FirstWord Pharma
Vertex's VX-445 triple combination regimen achieves main goals of two late-stage studies in CF - FirstWord Pharma
Vertex moves forward with regulatory filings after selecting VX-445 for triple-combination regimen in CF - FirstWord Pharma
Is Vertex Pharmaceuticals (VRTX) Among the Best Stocks to Buy According to Jim Simons’ Renaissance Technologies? - Insider Monkey
Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio? - Benzinga
VRTX Stock Down as Q1 Sales of New Drugs Miss Expectations - MSN
Final Trades: Vertex Pharma, Palantir, Wynn Resorts and Microsoft - CNBC
Vertex Pharmaceuticals Incorporated (VRTX) Surged On a Recovery in Investor Sentiment - Insider Monkey
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Vertex Pharmaceuticals Incorporated Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - Yahoo Finance
Vertex Pharmaceuticals Topples 10% On A Series Of First-Quarter Setbacks - MSN
3.85%
19.01%
大文字化:
|
ボリューム (24 時間):